10-Q: Avalo Therapeutics Advances Lead Asset, Extends Runway

Avalo Therapeutics reports increased R&D spend for its lead asset AVTX-009's Phase 2 trial, while extending its cash runway into 2028.

Summary

• Avalo Therapeutics, a clinical-stage biotechnology company, is focused on developing IL-1-based treatments for immune-mediated inflammatory diseases, with its lead asset AVTX-009 in a Phase 2 clinical trial for hidradenitis suppurativa (HS).
• For the six months ended June 30, 2025, the company reported a net loss of $33.9 million, an increase from $22.8 million for the same period in 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $20.8 million, a slight decrease from $22.5 million in the prior year period.
• Research and development expenses significantly increased to $23.2 million for the six months ended June 30, 2025, up from $6.7 million in the prior year, primarily due to the ongoing Phase 2 LOTUS trial for AVTX-009.
• As of June 30, 2025, Avalo had $113.3 million in cash, cash equivalents, and short-term investments, which is expected to fund operations for at least twelve months from the filing date and into 2028.
• The company expects to release topline results from the Phase 2 LOTUS trial for AVTX-009 in mid-2026.
• Avalo terminated its license agreement for AVTX-008, effective September 2025, and is exploring strategic alternatives for non-core assets Quisovalimab (AVTX-002) and AVTX-006.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur significant losses, which is typical for its stage, it has a clear strategic focus on its lead asset (AVTX-009) and has extended its cash runway into 2028, providing stability. The increased R&D spend reflects active progress on the Phase 2 trial, and the streamlining of non-core assets is a prudent financial move. The future hinges on the mid-2026 trial results, but the current financial position supports continued development.

Positives

• Existing cash and investments of $113.3 million are projected to fund operations into 2028, providing a longer runway than typical for a clinical-stage biotech.
• Progress continues on the lead asset, AVTX-009, with increased R&D investment in its Phase 2 LOTUS trial for hidradenitis suppurativa, indicating active development.
• Net cash used in operating activities slightly decreased to $20.8 million for the six months ended June 30, 2025, compared to $22.5 million in the prior year, suggesting some efficiency in cash burn despite increased R&D.
• The appointment of Dr. Rita Jain to the Board of Directors in June 2025 adds extensive experience in clinical development and regulatory strategy.
• The company is actively streamlining its pipeline by terminating the AVTX-008 license and exploring strategic alternatives for other non-core assets (AVTX-002, AVTX-006), focusing resources on AVTX-009.

Negatives

• The net loss increased to $33.9 million for the six months ended June 30, 2025, from $22.8 million in the prior year, indicating continued unprofitability.
• Cash and cash equivalents significantly decreased to $42.3 million as of June 30, 2025, from $134.5 million at December 31, 2024, although this was partially offset by a shift into short-term investments.
• The company continues to incur significant operating and cash losses since inception, a common but persistent challenge for clinical-stage biotechs.
• Other income, net, decreased significantly to $0.094 million for the six months ended June 30, 2025, from $19.5 million in the prior year, primarily due to the non-recurrence of a large accounting impact from warrant liability changes in 2024.

Risks

• There is no assurance that future financing or business development initiatives can be realized by the company, or if realized, what the terms may be.
• Raising capital through equity sales will dilute the ownership interest of existing stockholders, and terms may include liquidation or other preferences.
• If additional funds are raised through collaborations or licensing, the company might have to relinquish valuable rights to its technologies, future revenue streams, research programs, or product candidates.
• The FDA approval process is complex, time-consuming, and expensive, and there is no guarantee that products will obtain regulatory approval.
• Future research and development expenses beyond mid-2026 are difficult to predict and highly dependent on the outcome of the Phase 2 LOTUS trial.
• The fair value of the derivative liability related to out-licensed assets (AVTX-007 Milestones and Royalties) is based on unobservable inputs, and changes to these inputs could result in significant changes to the fair value measurement.
• The AVTX-501 Milestone, previously out-licensed, was deemed de minimis due to Johnson & Johnson discontinuing the related depression program, indicating a loss of potential future proceeds from that asset.

Future Outlook

The company's primary focus for 2025 is to continue operational execution on the development of AVTX-009, specifically progressing the Phase 2 LOTUS trial in HS, with topline results expected in mid-2026. Management's success evaluation hinges on advancing the pipeline towards commercialization or opportunistic out-licensing. The company expects its current cash and investments to fund operations into 2028 and plans to meet future cash needs through various financing and business development initiatives, including its at-the-market program, other equity financings, out-licensing, strategic alliances, asset sales, and/or mergers and acquisitions. Research and development expenses are expected to increase in 2025 compared to 2024 due to ongoing trial activities, with expenses beyond mid-2026 being highly dependent on the Phase 2 trial outcome.

Management Comments

• "Our focus in 2025 is continuing to execute operationally on the development of AVTX-009, most notably the progression of the Phase 2 (LOTUS) trial of AVTX-009, an anti-IL-1 (mAb), in HS."
• "We expect to release topline results from this trial in mid-2026."
• "Managements primary evaluation of the success of the Company is the ability to progress its pipeline forward toward commercialization or opportunistically out-licensing rights to indications or geographies."
• "We expect that our existing cash and cash equivalents and short-term investments are sufficient to fund operations for at least twelve months from the filing date of this Quarterly Report on Form 10-Q and we expect to fund operations into 2028."
• "The Company closely monitors its cash and cash equivalents and short-term investments and seeks to balance the level of cash and cash equivalents with our projected needs to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms."
• "We may satisfy any future cash needs through sales of equity securities under the Companys at-the-market program or other equity financings, out-licensing transactions, strategic alliances/collaborations, sale of programs, and/or mergers and acquisitions."

Industry Context

Avalo Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically targeting immune-mediated inflammatory diseases with its IL-1-based treatments. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Avalo's strategy of focusing on a lead asset (AVTX-009) while exploring strategic alternatives for non-core programs aligns with a common industry trend among smaller biotechs to streamline pipelines and conserve capital, especially when facing significant cash burn. The reliance on equity financing and potential partnerships for future funding is typical for companies at this stage, as they lack commercial revenue streams. The success of AVTX-009's Phase 2 trial will be a critical determinant of the company's future valuation and ability to attract further investment or partnerships, reflecting the high-risk, high-reward nature of drug development.

Comparison to Industry Standards

• Avalo's cash runway into 2028, based on current operating plans and existing capital, is a relatively strong position for a clinical-stage biotech, often exceeding the typical 12-18 month runway seen in the sector. This provides more flexibility for the AVTX-009 Phase 2 trial.
• The significant increase in R&D expenses (from $6.7 million to $23.2 million year-over-year for six months) is consistent with a company actively progressing a lead asset into a pivotal Phase 2 trial, such as the LOTUS trial for AVTX-009 in HS. This level of investment is comparable to peers like InflaRx (IFRX) or ChemoCentryx (CCXI, prior to acquisition) when their lead programs were in similar stages.
• The net loss of $33.9 million for six months is expected for a company without commercial products and heavy R&D. For instance, companies like Kymera Therapeutics (KYMR) or Denali Therapeutics (DNLI) also report substantial losses as they advance their pipelines.
• The Phase 2 LOTUS trial design (randomized, double-blind, placebo-controlled, parallel-group, ~222 adults, HiSCR75 primary endpoint) is a standard and robust approach for evaluating efficacy in hidradenitis suppurativa, aligning with industry best practices for clinical trials in inflammatory diseases.
• The company's strategy to divest or seek alternatives for non-core assets (e.g., AVTX-002, AVTX-006, AVTX-008) is a common practice among smaller biotechs to optimize resource allocation and focus on programs with the highest potential, similar to portfolio rationalization efforts seen at companies like Galapagos (GLPG) or smaller biotechs seeking to extend their cash runway.

Management Changes

Corporate Governance

Legal Proceedings

• The company may become party to various contractual disputes, litigation, and potential claims arising in the ordinary course of business, with reserves established when a loss is probable and estimable. Currently, no material adverse effect on financial position or results of operations is expected from such matters, except as disclosed.

Related Party Transactions

• In the fourth quarter of 2022, Avalo sold economic rights to future milestone and royalty payments for AVTX-501, AVTX-007, and AVTX-611 to ES Therapeutics, LLC (ES), an affiliate of Armistice Capital LLC. Armistice Capital LLC's chief investment officer, Steven Boyd, and managing director, Keith Maher, served on Avalo's Board until August 8, 2022. The transaction was approved in accordance with Avalo's related party transaction policy.
• In July 2019, Aevi (acquired by Avalo in 2020) entered into a royalty agreement with certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil (current CEO and Chairman) and Mike Cola (former CEO). This agreement provides a low-single digit percentage royalty on aggregate net sales of AVTX-006 in exchange for a one-time aggregate payment of $2.0 million. Avalo assumed this liability, treating it as an implicit obligation to repay funds advanced by the investors.

Stakeholder Impact

• **Shareholders:** Potential dilution from future equity raises (ATM program), but also benefit from extended cash runway and focused R&D on lead asset AVTX-009. Future share price highly dependent on AVTX-009 trial results.
• **Employees:** Increased stock-based compensation expense due to option and RSU grants, aligning their interests with company performance. Headcount additions support AVTX-009 program. Termination of AVTX-008 license and strategic review of other assets may impact employees associated with those programs.
• **Customers:** No direct impact as the company is clinical-stage and ceased sales of its only commercial product (Millipred). Future customers would benefit from successful development of AVTX-009.
• **Suppliers/Creditors:** Increased accounts payable due to ongoing clinical work and vendor invoices related to the LOTUS trial, indicating active engagement with suppliers. The extended cash runway provides greater assurance for creditors.
• **Regulatory Authorities:** Continued engagement with regulatory bodies (e.g., FDA) through ongoing clinical trials and potential future applications for AVTX-009.

Next Steps

• Continue to execute operationally on the development of AVTX-009, specifically progressing the Phase 2 LOTUS trial in HS.
• Release topline results from the Phase 2 LOTUS trial in mid-2026.
• Prepare for the next stage of development for AVTX-009 in HS, and consider further indication expansion for the asset.
• Explore additional opportunities to make an impact in prevalent indications with significant unmet needs.
• Acquire or in-license rights to and/or develop targeted, complementary differentiated preclinical and clinical stage compounds that treat immune mediated disease.
• Opportunistically out-license rights to compounds, indications, or geographies.
• Monitor estimates for commercial liabilities related to the Millipred product, including sales returns and profit share reconciliation.
• Continue to monitor milestones and royalties for in-licensed and out-licensed compounds at each reporting period.

Key Dates

Recommendation

Avalo Therapeutics is a clinical-stage biotech with a clear focus on its lead asset, AVTX-009, which is progressing through a pivotal Phase 2 trial. The company has prudently extended its cash runway into 2028, mitigating immediate liquidity concerns, and is streamlining its pipeline by divesting non-core assets. However, the company remains unprofitable, and its future valuation is heavily reliant on the success of the AVTX-009 trial, with topline results not expected until mid-2026. Given the significant time until key data readout and the inherent risks of clinical development, a 'hold' recommendation is appropriate. Investors should monitor the progress of the LOTUS trial and the company's cash burn rate, as well as any further capital raising activities, before making a more definitive investment decision.

Keywords

Biotechnology, Clinical Stage, IL-1, Inflammatory Diseases, Hidradenitis Suppurativa, HS, AVTX-009, Phase 2 Trial, LOTUS Trial, Drug Development, SEC Filing, 10-Q, Biopharma, Immunology